Single Cell Technology, Inc.
Single Cell Technology, Inc. is a San Jose-based biotech contract research organization providing fee-for-service antibody discovery through its proprietary AbTheneum™ single B cell screening platform, serving top 10 pharmaceutical companies and small virtual biotechs across immuno-oncology, CNS, infectious disease, and autoimmune therapeutic areas.
- Company typePrivate
- Founded2008
- HeadquartersSan Jose, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Single Cell Technology, Inc. does
Single Cell Technology, Inc. is a San Jose, California-based contract research organization founded in 2008 that began commercial antibody discovery operations in 2016. The company provides B2B antibody discovery services to large pharmaceutical companies (including top 10 pharma) and small virtual biotech firms across therapeutic areas spanning immuno-oncology, central nervous system diseases, infectious disease, and autoimmune conditions. The company operates with a 1-10 person team under founder Chun-Nan Chen, who serves concurrently as CEO and CSO, with Erik Babajanian as CFO.
The company's technical core is the proprietary AbTheneum™ platform — a single B cell antibody discovery system that screens antibodies in parallel using three integrated components: picoliter well deposition (20,000+ cells placed in wells under 200 picoliters each), antibody array capture on slides for multiplex fluorescent screening (antigen binding, epitope specificity, cross-reactivity, blocking), and a custom DNA microarray that sequences thousands of full-length IgG sequences in parallel via barcodes and clonotype clustering. The architecture is designed to eliminate the picking bias inherent to hybridoma and phage display workflows. Add-on capabilities include SurfScreen for membrane-bound targets (GPCRs, virus-like particles), First Look Assay for low-cost pre-campaign evaluation, and integrated cell-based functional bioassays including ADCC reporter assays and PBMC-based validation.
Revenue is generated through fee-for-service antibody discovery campaigns. Clients submit target antigens and engage Single Cell Technology to design and execute screening campaigns, receiving antibody candidates with full-length sequences, screening data, and characterization packages — typically delivered as a complete data package within three weeks of cell harvest, with reported >98% success rate on antigen binding after expression. Go-to-market is sales-led direct engagement with pharma discovery and translational teams rather than channel partners, supported by scientific content marketing (case studies, conference presentations at Antibody Engineering & Therapeutics, webinars). The company holds a core technology alliance with Miltenyi Biotec for cell isolation workflows including B cell isolation kits and MACSQuant Tyto cell sorting, enabling human PBMC-based campaigns in addition to standard murine, rat, and rabbit host systems. The company has received a single early-stage funding tranche of $323,777 (2012, investors undisclosed) and remains privately held with no disclosed institutional venture capital.
Single Cell Technology, Inc. firmographics
Firmographics- Name
- Single Cell Technology, Inc.
- Legal name
- Single Cell Technology, Inc.
- Website
- https://singlecelltechnology.com
- Company type
- Private
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Single Cell Technology, Inc. is a San Jose-based biotech contract research organization providing fee-for-service antibody discovery through its proprietary AbTheneum™ single B cell screening platform, serving top 10 pharmaceutical companies and small virtual biotechs across immuno-oncology, CNS, infectious disease, and autoimmune therapeutic areas.
- Ownership category
- akta.pro rank
Single Cell Technology, Inc. industry classification
Industry- Product category
- Antibody Discovery Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)
- akta.pro secondary industry
- Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling) (HLAAAIAF)
Keywords
Where Single Cell Technology, Inc. is headquartered
LocationHeadquarters
- HQ city
- San Jose
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Single Cell Technology, Inc. business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Antibody Discovery Services: Fee-for-service antibody discovery campaigns using the AbTheneum platform. Clients submit target antigens and receive antibody candidates with full-length sequences, screening data, and characterization. Pricing is likely project-based based on campaign complexity.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Single Cell Technology, Inc. product offering
Product offeringCore offering
Single Cell Technology provides fee-for-service antibody discovery using its proprietary AbTheneum™ platform, which deposits single B cells into picowells, captures their secreted antibodies on slides within hours, and sequences full-length IgG using a custom DNA microarray. Clients submit target antigens and receive antibody candidates with full-length sequences, multi-layered screening data (antigen binding, epitope, cross-reactivity, blocking), and functional characterization in approximately three weeks.
Product overview
Single Cell Technology offers a unified antibody discovery platform centered on AbTheneum™, with specialized add-on modules including SurfScreen for membrane target screening and First Look Assay for pre-campaign sample evaluation. The company also provides various screening assay capabilities including epitope binning, blocking assays, competition assays, and cell-based functional bioassays.
Differentiator
Problem solved
Functional benefit
Brands
- AbTheneum: Single Cell Technology's proprietary platform for single B cell antibody discovery that screens all antibodies in parallel for multiple parameters without picking bias.
Products and services
- AbTheneum™ Antibody Discovery Platform Single B cell antibody discovery service that screens antibodies secreted by cells within hours using picoliter picowell technology, captures full-length IgG sequences on a custom DNA microarray, and delivers candidates with multi-parameter screening data (antigen binding, epitope, cross-reactivity, blocking) in about three weeks for pharmaceutical and biotech clients.
- SurfScreen Module of the AbTheneum platform for screening antibodies against membrane targets using cell-based screens, combining cell-based and recombinant (SimulScreen) approaches to enrich data for membrane-bound antigens.
- First Look Assay Low-cost, small-scale antibody screening study performed on multiple samples before a full AbTheneum campaign, using the platform's cell isolation and antibody screening for sample comparison and go/no-go decisions.
Companies that use Single Cell Technology, Inc.
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles2 records
Single Cell Technology, Inc. technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature8 records
Single Cell Technology, Inc. partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Miltenyi BioteccoreCollaboration with Miltenyi Biotec for cell isolation workflows. Miltenyi sourced peripheral mononuclear blood cells (PBMCs) from donors and provided the Class-Switched Memory B Cell Isolation Kit (catalog # 130-093-617) and B Cell Expansion Kit (catalog # 130-106-196). The partnership enables AbTheneum to work with human cells using Miltenyi's MACSQuant Tyto cell sorter for antigen-specific cell enrichment.
Scale indicators9 records
Recent moves6 records
Expansion highlights5 records
Single Cell Technology, Inc. competitors and assessment
Company assessmentMarket position
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Single Cell Technology, Inc. social profiles
Digital presenceSingle Cell Technology, Inc. compliance and trust
Trust signalCompliance2 records
Single Cell Technology, Inc. financial estimates
Financial estimateRevenue estimate
Valuation estimate
Single Cell Technology, Inc. leadership team
Management profileNumber of profiles
Profiles2 records
Single Cell Technology, Inc. funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Single Cell Technology, Inc. M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Single Cell Technology, Inc.
What does Single Cell Technology, Inc. do?
Single Cell Technology provides fee-for-service antibody discovery using its proprietary AbTheneum™ platform, which deposits single B cells into picowells, captures their secreted antibodies on slides within hours, and sequences full-length IgG using a custom DNA microarray. Clients submit target antigens and receive antibody candidates with full-length sequences, multi-layered screening data (antigen binding, epitope, cross-reactivity, blocking), and functional characterization in approximately three weeks.
Is Single Cell Technology, Inc. a public or private company?
Single Cell Technology, Inc. is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Single Cell Technology, Inc. founded?
Single Cell Technology, Inc. was founded in 2008. It employs 1 to 10 people.
Where is Single Cell Technology, Inc. based?
Single Cell Technology, Inc. is headquartered in San Jose, United States, in the North America region.
How does Single Cell Technology, Inc. make money?
One revenue line is on record: antibody Discovery Services.
Does Single Cell Technology, Inc. have an API?
No public API is recorded for Single Cell Technology, Inc..
What industry is Single Cell Technology, Inc. in?
Single Cell Technology, Inc.'s product category is Antibody Discovery Services. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAAIAF, Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling). Its NAICS code is 541714 and its SIC code is 8731.